ATE418977T1 - Verwendung von phenylacetylderivaten zur herstellung eines arzneimittels zur behandlung der von-hippel-lindau-erkrankung - Google Patents
Verwendung von phenylacetylderivaten zur herstellung eines arzneimittels zur behandlung der von-hippel-lindau-erkrankungInfo
- Publication number
- ATE418977T1 ATE418977T1 AT06736775T AT06736775T ATE418977T1 AT E418977 T1 ATE418977 T1 AT E418977T1 AT 06736775 T AT06736775 T AT 06736775T AT 06736775 T AT06736775 T AT 06736775T AT E418977 T1 ATE418977 T1 AT E418977T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- von hippel
- production
- lindau disease
- phenylacetyl
- Prior art date
Links
- 208000006542 von Hippel-Lindau disease Diseases 0.000 title abstract 6
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- -1 PHENYLACETYL Chemical class 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 159000000000 sodium salts Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 abstract 2
- XBJLFHMAIQTBJX-JTQLQIEISA-N (4s)-5-amino-5-oxo-4-[(2-phenylacetyl)amino]pentanoic acid Chemical compound OC(=O)CC[C@@H](C(=O)N)NC(=O)CC1=CC=CC=C1 XBJLFHMAIQTBJX-JTQLQIEISA-N 0.000 abstract 1
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960003424 phenylacetic acid Drugs 0.000 abstract 1
- 239000003279 phenylacetic acid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65975905P | 2005-03-08 | 2005-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE418977T1 true ATE418977T1 (de) | 2009-01-15 |
Family
ID=36691615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06736775T ATE418977T1 (de) | 2005-03-08 | 2006-03-02 | Verwendung von phenylacetylderivaten zur herstellung eines arzneimittels zur behandlung der von-hippel-lindau-erkrankung |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060205818A1 (de) |
| EP (1) | EP1855665B1 (de) |
| AT (1) | ATE418977T1 (de) |
| DE (1) | DE602006004568D1 (de) |
| EA (1) | EA012908B1 (de) |
| WO (1) | WO2006096481A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2635539C2 (ru) * | 2016-03-10 | 2017-11-13 | Федеральное государственное бюджетное учреждение науки Институт высокомолекулярных соединений Российской академии наук | Полимерные водорастворимые производные 4-фенил-бутановой кислоты, обладающие противоопухолевой активностью |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559325A (en) * | 1981-12-15 | 1985-12-17 | Burzynski Stanislaw R | Purified antineoplaston fractions and methods of treating neoplastic disease |
| US6037376A (en) * | 1991-10-21 | 2000-03-14 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for therapy of cancer |
| US5391575A (en) * | 1994-05-04 | 1995-02-21 | Burzynski; Stanislaw R. | Method for treating neurofibromatosis |
| CA2254772C (en) * | 1996-05-14 | 2004-01-27 | Stanislaw R. Burzynski | Liposomal antineoplaston therapies with markedly improved antineoplastic activity |
| US6258849B1 (en) * | 1998-07-23 | 2001-07-10 | Stanislaw R. Burzynski | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| EP1117397A1 (de) * | 1998-08-31 | 2001-07-25 | Sugen, Inc. | Geometrisch verhinderte 2-indolinonderivate als modulatoren der protein kinase aktivität |
| BR9916407A (pt) * | 1998-12-21 | 2001-09-25 | Univ Monash | Detecção e tratamento de doenças dos rins |
| AU3281600A (en) * | 1999-02-27 | 2000-09-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases |
| AU2002303892A1 (en) * | 2001-05-30 | 2002-12-09 | Jingrong Cui | 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
-
2006
- 2006-03-01 US US11/365,289 patent/US20060205818A1/en not_active Abandoned
- 2006-03-02 EP EP06736775A patent/EP1855665B1/de active Active
- 2006-03-02 EA EA200701920A patent/EA012908B1/ru active IP Right Revival
- 2006-03-02 DE DE602006004568T patent/DE602006004568D1/de active Active
- 2006-03-02 AT AT06736775T patent/ATE418977T1/de not_active IP Right Cessation
- 2006-03-02 WO PCT/US2006/007511 patent/WO2006096481A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| US20060205818A1 (en) | 2006-09-14 |
| DE602006004568D1 (de) | 2009-02-12 |
| EA200701920A1 (ru) | 2008-02-28 |
| EP1855665B1 (de) | 2008-12-31 |
| EP1855665A1 (de) | 2007-11-21 |
| WO2006096481A1 (en) | 2006-09-14 |
| EA012908B1 (ru) | 2010-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117656T1 (el) | Επιλογες θεραπειας για τη νοσο του fabry | |
| CY1117326T1 (el) | Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson | |
| ATE476414T1 (de) | Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen | |
| DE502007002101D1 (de) | Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen | |
| EA200801580A1 (ru) | Новые производные пирониндола и способ их получения | |
| DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| ATE442142T1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| EA201200952A1 (ru) | Производные пиразина и их применение для лечения неврологических нарушений | |
| HUP0301749A2 (hu) | Acilfenil-karbamid-származékok, eljárás az elżállításukra és gyógyszerkénti alkalmazásuk | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| ATE411399T1 (de) | Behandlung der huntington's krankheit mit epa | |
| EA201100778A1 (ru) | Гетероциклические замещенные соединения в качестве ингибиторов hif | |
| ATE510536T1 (de) | Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen | |
| CY1111353T1 (el) | Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης | |
| NO20082566L (no) | Kombinasjon av AZ2171 og permetrexed | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| ATE311866T1 (de) | Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln zur behandlung von erkrankungen rheumatischer natur | |
| EA200900269A1 (ru) | Лекарственные комбинации для лечения заболеваний дыхательных путей | |
| ATE252383T1 (de) | Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| ATE418977T1 (de) | Verwendung von phenylacetylderivaten zur herstellung eines arzneimittels zur behandlung der von-hippel-lindau-erkrankung | |
| ATE444754T1 (de) | Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse | |
| ATE445394T1 (de) | Verwendung von citrullin zur herstellung eines arzneimittels zur behandlung von ans altern oder an eine bestrahlung gebundener intestinaler insuffizienz | |
| ATE491443T1 (de) | Verwendung des agomelatins zur herstellung eines medikamentes zur behandlung der bipolaren erkrankungen | |
| ATE239492T1 (de) | Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen | |
| DE602006021594D1 (de) | Verbindung zur prävention und behandlung von links |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |